MOTS-c

Step	Weeks	Dose	Purpose
Weeks 1-2	—	5 mg	Establish baseline metabolic response
Weeks 3-12	—	10 mg	Full metabolic and longevity protocol

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

Foundational Discovery - Lee 2015

Lee et al., 2015 (Cell Metabolism) [PMID:25738459] provided the foundational characterization of MOTS-c:

• Identification of MOTS-c as a 16-amino-acid peptide encoded in the 12S rRNA region of mitochondrial DNA
• AMPK activation via inhibition of the folate cycle and its tethered de novo purine biosynthesis, demonstrated in cell culture and animal models
• Exogenous MOTS-c in diet-induced obese mice produced:
  • Reduced diet-induced obesity without reduced food intake
  • Improved glucose tolerance and insulin sensitivity
  • Reduced visceral adiposity
  • Prevention of high-fat-diet-induced and age-dependent insulin resistance
• Plasma MOTS-c levels in humans decline with age

This paper established MOTS-c as a biologically significant metabolic regulator and launched the entire MOTS-c research program. It is the single most important citation in the field.

Exercise and Aging - Reynolds 2021

Reynolds et al., 2021 (Nature Communications) [PMID:33473109] examined MOTS-c in the context of exercise and aging:

• Exercise increases circulating MOTS-c in human subjects
• MOTS-c enhanced physical performance in young, middle-aged, and old mice
• Late-life initiated intermittent MOTS-c treatment (3x/week) increased physical capacity and healthspan in mice
• Muscle-related effects included regulation of nuclear genes tied to metabolism and proteostasis, and improved myoblast adaptation to metabolic stress

This paper strengthened the case for MOTS-c as an exercise-mimetic and established the aging-related narrative that has driven interest in MOTS-c as a longevity intervention.

Mechanistic Extension - Kim 2018

Kim et al., 2018 (Cell Metabolism) [PMID:29983246] showed that under metabolic stress such as glucose restriction, MOTS-c translocates to the nucleus and regulates stress-responsive nuclear gene expression in an AMPK-dependent manner - including antioxidant-response-element (ARE) genes, via interaction with the transcription factor NRF2 (NFE2L2). This established MOTS-c as a mediator of mitonuclear communication and helped explain how a mitochondrial-encoded peptide produces genome-level metabolic effects. (The upstream folate-cycle / de novo purine biosynthesis mechanism was defined earlier, in Lee 2015 [PMID:25738459].)

Human Research - Still Early

Human research on exogenous MOTS-c supplementation is significantly less developed than the animal/mechanistic literature. Published human data includes:

• Observational studies documenting age-related MOTS-c decline
• Studies correlating endogenous MOTS-c levels with metabolic health markers
• Small pilot interventional studies (mostly unpublished or in early phases)

As of 2026, no large-scale randomized controlled trials of exogenous MOTS-c administration in humans have been published. Clinical-stage development is early, and there is no registered/published Phase I trial of native MOTS-c itself (a separate engineered MOTS-c analog, CB4211, was studied in early human trials but is a different molecule). Most efficacy claims in the peptide-therapy community rely on the robust animal and mechanistic data plus modest human observational correlations.

This is a genuine evidence gap. Users considering MOTS-c should understand the bulk of efficacy evidence comes from preclinical work, not human controlled trials.

Safety Signal - Limited Human Data

Controlled human trial safety data for exogenous MOTS-c is essentially absent. Within the limited observational and anecdotal community reports at typical research doses (5-10 mg SC 2-3x weekly), MOTS-c has been described as generally well tolerated, with reported effects including:

• Mild injection site reactions
• Occasional transient fatigue in the first week
• No serious adverse events documented in the published literature
• No clear hypoglycemia signal despite AMPK activation

However, long-term safety data is essentially absent in humans. Theoretical concerns include:

• AMPK activation opposes mTOR; chronic MOTS-c could theoretically produce mTOR-suppression effects (reduced muscle protein synthesis, altered immune function)
• Systemic mitochondrial biogenesis has unknown long-term implications
• Effects on tumor cells - AMPK is both anti-cancer (in some contexts, via mTOR suppression) and pro-cancer (in others, via energy preservation under stress); the MOTS-c cancer profile is not established

Aging and Longevity Research

MOTS-c is actively being investigated as a potential longevity intervention:

• Preclinical work in aged mice shows restoration of metabolic parameters and exercise capacity
• Human observational data supports the age-decline narrative
• Theoretical mechanism (AMPK activation, mitochondrial biogenesis, metabolic flexibility improvement) aligns with established longevity pathways

Clinical longevity trials are in planning or early-phase stages; no validated longevity outcome data exists yet.

Reported Effects (limited human data)

• Injection site reactions — Mild erythema, transient itching at SC injection site. Site rotation minimizes. Probably the single most reported issue.
• Transient fatigue — Some users report mild fatigue in the first week of dosing. Usually resolves spontaneously by week 2. May reflect the AMPK-mediated metabolic shift as the body adapts to the new signaling input.
• Mild headache — Uncommon; typically responsive to hydration.
• Nausea — Rare; mild when reported.

Theoretical Concerns

Because human data is limited, the side effect profile is largely theoretical and based on the known effects of AMPK activation and mitochondrial biogenesis:

• Mild blood glucose reduction — AMPK-mediated glucose uptake could theoretically cause modest hypoglycemia, though clinical reports have not emphasized this effect. Users on insulin, sulfonylureas, or other hypoglycemics should monitor glucose during first doses.
• Muscle protein synthesis reduction — AMPK activation opposes mTOR. Theoretical concern that chronic MOTS-c could reduce anabolic signaling and impair muscle-building protocols. In practice, the effect appears modest and is often offset by improved mitochondrial function supporting training capacity.
• Cellular stress response activation — MOTS-c signaling is a stress-response peptide; chronic pharmacologic activation could theoretically alter baseline stress responses in unpredictable ways.
• Tumor cell effects — Complex. AMPK activation can be anti-cancer (via mTOR suppression reducing cell growth) or pro-cancer (via energy preservation supporting tumor cell survival under stress). MOTS-c's net effect in occult malignancy is unknown.

Unknown Long-term

• Effects on longevity have not been validated in humans
• Effects on immune function are unknown
• Effects on reproduction are unknown
• Effects on cognitive function are unknown (though the related peptide humanin has been studied in neuroprotection)
• Pregnancy and lactation effects completely unstudied

Contraindications

Pregnancy, lactation, active malignancy (until risk/benefit better characterized), concurrent use of metformin or direct AMPK activators (potentially additive), known hypersensitivity. Use caution in anyone with brittle diabetes due to the AMPK mechanism.

Signs to Stop

• Any severe hypoglycemic episode (unlikely but possible in predisposed users)
• Any unexpected severe fatigue
• Significant hypersensitivity reaction
• Any new or worsening symptoms that could plausibly be related

Because the human safety database is small, low threshold for discontinuation and re-evaluation is appropriate when in doubt.